1.
Background: Rituximab is a promising steroid sparing agent used in the treatment of moderate to severe pemphigus vulgaris. Its exact place in the algorithm of pemphigus t[...]
2018 | Clinical medicine|Basic medicine | Text|Tabular |
Version 1
|
2.
Introduction: Autoantibodies (autoAbs) against desmoglein-1 (DSG1) and desmoglein-3 (DSG3) have conventionally been studied and well accepted in the pathogenesis of pemph[...]
2020 | Clinical medicine | Tabular |
Version 1
|